ID   K562/D1-9
AC   CVCL_D205
DR   Wikidata; Q54899408
RX   PubMed=8687117;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:41977; Daunorubicin (Daunomycin).
CC   Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C9110; Blast phase chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0004 ! K-562
SX   Female
AG   53Y
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 29-06-23; Version: 19
//
RX   PubMed=8687117;
RA   Urasaki Y., Ueda T., Yoshida A., Fukushima T., Takeuchi N., Tsuruo T.,
RA   Nakamura T.;
RT   "Establishment of a daunorubicin-resistant cell line which shows
RT   multi-drug resistance by multifactorial mechanisms.";
RL   Anticancer Res. 16:709-714(1996).
//